Edgewise to advance heart drug into Phase 3 following mid-stage data update

June 16, 2026 11:40 AM EDT R&D Edge­wise to ad­vance heart drug in­to Phase 3 fol­low­ing mid-stage da­ta up­date Ayisha Sharma News Reporter Edge­wise Ther­a­peu­tics has shared plans to ad­vance its drug can­di­date for a ge­net­ic heart dis­ease in­to a reg­is­tra­tional study on the back of up­dat­ed Phase … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER